Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Lim B, Potter DA, Salkeni MA, Silverman P, Haddad TC, Forget F, Awada A, Canon JL, Danso M, Lortholary A, Bourgeois H, Tan-Chiu E, Vincent S, Bahamon B, Galinsky KJ, Patel C, Neuwirth R, Leonard EJ, Diamond JR. Lim B, et al. Among authors: galinsky kj. Clin Cancer Res. 2021 Jun 15;27(12):3329-3338. doi: 10.1158/1078-0432.CCR-20-4131. Epub 2021 Apr 5. Clin Cancer Res. 2021. PMID: 33820779
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
García-Sáenz JÁ, Martínez-Jáñez N, Cubedo R, Jerez Y, Lahuerta A, González-Santiago S, Ferrer N, Ramos M, Alonso-Romero JL, Antón A, Carrasco E, Chen J, Neuwirth R, Galinsky K, Vincent S, Leonard EJ, Slamon D. García-Sáenz JÁ, et al. Clin Cancer Res. 2022 Mar 15;28(6):1107-1116. doi: 10.1158/1078-0432.CCR-21-2652. Clin Cancer Res. 2022. PMID: 34980598 Free PMC article. Clinical Trial.
An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.
Shanbhag NM, Padmanabhan JL, Zhang Z, Harel BT, Jia H, Kangarloo T, Yin W, Dowling AV, Laurenza A, Khudyakov P, Galinsky K, Latzman RD, Simuni T, Weintraub D, Horak FB, Lustig C, Maruff P, Simen AA. Shanbhag NM, et al. JAMA Neurol. 2025 Jan 6. doi: 10.1001/jamaneurol.2024.4519. Online ahead of print. JAMA Neurol. 2025. PMID: 39761063
Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial.
Leonard MM, Silvester JA, Leffler D, Fasano A, Kelly CP, Lewis SK, Goldsmith JD, Greenblatt E, Kwok WW, McAuliffe WJ, Galinsky K, Siegelman J, Chow IT, Wagner JA, Sapone A, Smithson G. Leonard MM, et al. Gastroenterology. 2021 Feb;160(3):720-733.e8. doi: 10.1053/j.gastro.2020.10.040. Epub 2020 Oct 29. Gastroenterology. 2021. PMID: 33130104 Free PMC article. Clinical Trial.
Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia.
Reijnders TDY, Laterre PF, François B, Sánchez García M, van Engelen TSR, Sie D, Scicluna BP, Ostanin DV, Galinsky KJ, Butler JM, Lombardo E, van der Poll T; SEPCELL study group. Reijnders TDY, et al. Among authors: galinsky kj. Thorax. 2024 Oct 16;79(11):1086-1090. doi: 10.1136/thorax-2024-222026. Thorax. 2024. PMID: 39322407 Free PMC article. Clinical Trial.
Response to Shen et al.
Galinsky KJ, Bhatia G, Loh PR, Georgiev S, Mukherjee S, Patterson NJ, Price AL. Galinsky KJ, et al. Am J Hum Genet. 2016 Nov 3;99(5):1220-1221. doi: 10.1016/j.ajhg.2016.09.013. Am J Hum Genet. 2016. PMID: 27814525 Free PMC article. No abstract available.
11 results